Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Thoracic Cancer|October 5, 2019
Prognostic significance of IMMT expression in surgically-resected lung adenocarcinomaYasuhiro Hiyoshi, Yuichi Sato, Masaaki Ichinoe, et al.
Human Pathology|January 11, 2018
Prognostic significance of S100A16 subcellular localization in lung adenocarcinomaMakoto Kobayashi, Ryo Nagashio, Keita Saito, et al.
Plos One|April 20, 2019
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancerMasayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, et al.
Oncology|May 11, 2023
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase InhibitorsYuki Akazawa, Satoshi Igawa, Kaori Yamada, et al.
Oncology|April 27, 2018
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR MutationsNoriko Nishinarita, Satoshi Igawa, Masashi Kasajima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 14, 2012
[Pemetrexed as second-line treatment and beyond for elderly patients with advanced non-small-cell lung cancer]Sakiko Otani, Satoshi Igawa, Sachiyo Maki, et al.
Oncology|February 3, 2018
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance StatusSatoshi Igawa, Masayuki Shirasawa, Tomoya Fukui, et al.
Thoracic Cancer|August 21, 2018
Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective studyHideyuki Sone, Satoshi Igawa, Masashi Kasajima, et al.
Thoracic Cancer|June 6, 2018
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance statusSatoshi Igawa, Masayuki Shirasawa, Takahiro Ozawa, et al.
Thoracic Cancer|February 15, 2020
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumabTomoya Fukui, Shinji Hosotani, Itaru Soda, et al.
Pageof 11